About
Glycorex Transplantation AB is a Swedish biotechnology and medical technology company based in Lund, specializing in organ transplantation and blood treatment solutions. Founded in 1996, the company utilizes advanced nanosurgical technology to selectively remove antibodies from blood, enhancing medical treatments. The flagship product, Glycosorb-ABO, allows organ transplants across incompatible blood groups by eliminating blood group antibodies. This innovation has significantly improved the success rates of transplants, including kidney, liver, and heart procedures, and has been implemented in various countries. Glycorex also offers Glycosorb® UBP, a device that produces universal blood plasma by removing antibodies, aimed at increasing global blood plasma availability. Additionally, the company is developing new extracorporeal blood treatment products for autoimmune diseases, with clinical trials planned. Glycorex's expertise in biologically active carbohydrates and blood treatments positions it as a leader in the field, providing solutions that benefit hospitals, transplant centers, and healthcare providers worldwide.
Technologies
Keywords
Company Information
-
Employees 11
-
Founded 1996
Location
27 Scheelevaegen, Lund, Skane County, Sweden, 223 63
